Gemtuzumab ozogamicin plus midostaurin in conjunction with standard intensive therapy for FLT3-mutated acute myeloid leukemia patients - Czech Center experience
| Authors | |
|---|---|
| Year of publication | 2023 |
| Type | Article in Periodical |
| Magazine / Source | Haematologica |
| MU Faculty or unit | |
| Citation | |
| Web | https://haematologica.org/article/view/haematol.2022.282263 |
| Doi | http://dx.doi.org/10.3324/haematol.2022.282263 |
| Keywords | Gemtuzumab ozogamicin; midostaurin; acute myeloid leukemia |
| Attached files | |
| Description | For more than four decades, conventional therapy for acute myeloid leukemia (AML) has been represented by cytarabine/anthracycline-containing regimens, followed by consolidation therapy, including allogeneic hematopoietic stem cell transplantation (allo-HSCT). In recent years, approach to the treatment of AML has significantly shifted toward the use of novel and effective, target-directed therapies, including anti-CD33 immunoconjugate, gemtuzumab ozogamicin (GO), and inhibitor of mutant FMS-like tyrosine kinase 3 (FLT3), midostaurin (MIDO). |
| Related projects: |